CalEthos, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CalEthos, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Apr 9, 2024 |
| FY2017 | Dec 31, 2016 | $3.7K | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $93.1K | Mar 21, 2017 |
| FY2015 | Dec 31, 2014 | $104.6K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 31, 2015 |
| FY2014 | Sep 30, 2013 | $0 | Mar 31, 2015 |
| FY2014 | Dec 31, 2012 | $0 | Mar 31, 2015 |
| FY2013 | Sep 30, 2012 | $0 | Jan 14, 2014 |
| FY2012 | Sep 30, 2011 | $0 | Dec 31, 2012 |
| FY2011 | Sep 30, 2010 | $0 | May 30, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.50M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($12.59M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.63M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $2.18M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | ($6.75M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($756.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.50M) | Jun 30, 2021 |
| FY2019 | Dec 31, 2018 | ($228.0K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($25.0K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($50.8K) | Mar 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.06M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.47M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $3.92M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | ($6.15M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($391.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.19M) | Jun 30, 2021 |
| FY2017 | Dec 31, 2017 | ($25.6K) | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | ($46.1K) | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $13.9K | Mar 21, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.42M | Mar 27, 2014 |
| FY2013 | Sep 30, 2013 | $0 | Jan 14, 2014 |
| FY2012 | Sep 30, 2012 | $0 | Dec 31, 2012 |
| FY2011 | Sep 30, 2011 | $0 | Jan 13, 2012 |
| FY2011 | Sep 30, 2010 | $0 | Jan 13, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($750.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($859.0K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($35.0K) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($820.0K) | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | ($565.0K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($182.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($418.0K) | Jun 30, 2021 |
| FY2019 | Dec 31, 2018 | ($45.0K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $22.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $297.0K | Mar 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | ($51.5K) | Mar 31, 2014 |
| FY2013 | Sep 30, 2013 | $0 | Jan 14, 2014 |
| FY2013 | Sep 30, 2012 | $0 | Jan 14, 2014 |
| FY2012 | Sep 30, 2011 | $0 | Dec 31, 2012 |
| FY2011 | Sep 30, 2010 | $0 | May 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $295.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.15M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.58M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $2.07M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $3.09M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $125.0K | Jun 30, 2021 |
| FY2019 | Dec 31, 2018 | $14.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $29.0K | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Apr 2, 2025 |
| FY2021 | Dec 31, 2021 | $3.63M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $1.33M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $686.0K | Jun 30, 2021 |
| FY2019 | Dec 31, 2018 | $180.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.0K | Apr 1, 2019 |
| FY2016 | Dec 31, 2015 | $2.88M | Mar 21, 2017 |
| FY2015 | Dec 31, 2014 | $2.62M | Mar 30, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.80M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.32M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $1.56M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($3.14M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2021 | ($540.0K) | Apr 9, 2024 |
| FY2022 | Dec 31, 2020 | ($1.32M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($561.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($166.0K) | Jun 30, 2021 |
| FY2019 | Dec 31, 2017 | $3.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $28.0K | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.37M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($31.87M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.28M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($14.65M) | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | ($16.83M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($10.08M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($9.33M) | Jun 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.83M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($7.60M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.57M) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $287.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $286.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $308.0K | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $2.07M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $3.05M | Apr 17, 2023 |
| FY2020 | Dec 31, 2019 | $123.0K | Jun 30, 2021 |
| FY2018 | Dec 31, 2017 | $7.0K | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $29.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $180.4K | Mar 28, 2018 |
| FY2016 | Dec 31, 2014 | $230.2K | Mar 21, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 25.73M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 24.35M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | 24.50M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | 26.00M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 16.63M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 16.63M | Jun 30, 2021 |
| FY2019 | Dec 31, 2018 | 16.63M | Mar 30, 2020 |
| FY2020 | Dec 31, 2017 | 630,207 | Jun 30, 2021 |
| FY2017 | Dec 31, 2016 | 15.72M | Mar 28, 2018 |